Last reviewed · How we verify
Lack or loss of sexual desire
Approved treatments
- Vyleesi (Autoinjector) · Cosette
Bremelanotide activates melanocortin receptors, primarily MC1R and MC4R, to potentially improve HSDD, though the exact mechanism is unknown. - Addyi · Sprout Pharms
Addyi works by increasing the levels of neurotransmitters dopamine, serotonin, and norepinephrine in the brain, which helps to regulate sexual desire.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Lack or loss of sexual desire patent landscape — cliff calendar, originator estates, attackable patents
- Lack or loss of sexual desire treatment landscape brief
- Lack or loss of sexual desire treatment updates RSS
Frequently asked questions about Lack or loss of sexual desire
What drugs treat Lack or loss of sexual desire?
Tracked treatments include Vyleesi (Autoinjector), Addyi.
What is the treatment for Lack or loss of sexual desire?
Standard treatment for Lack or loss of sexual desire includes Vyleesi (Autoinjector), Addyi. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Lack or loss of sexual desire patent cliff · Lack or loss of sexual desire CI report
- Treatment: Vyleesi (Autoinjector) · Cosette
- Treatment: Addyi · Sprout Pharms
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing